ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma

Contributed by: Business Wire

Logo

Tags

Medical Devices

Health

Optical

Clinical Trials

Health Technology

Open-Angle Glaucoma

More Like This

PR Newswire associated0

ViaLase Receives CE Mark for First Femtosecond Laser for the Treatment of Glaucoma, the ViaLase® Laser

ViaLase Announces Strategic Leadership Transitions to Support Commercial Growth

PR Newswire associated0

ViaLase to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS)

Sanoculis Receives CE Mark for MINT® Product for the Treatment of Glaucoma

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision

LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects

MedLumics New CEO and Board Member Announces 10 Patients Treated in First in Man (FIM) Clinical Trial With the Real-Time Visually Guided AblaView PFA System